NCT06665100View on ClinicalTrials.gov

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

May 31, 2026

Conditions
Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
Interventions
DRUG

PUL-042

Pam2 : ODN (PUL-042) PUL-042 Inhalation Solution

DRUG

Placebo

Sterile Saline for Inhalation

Trial Locations (11)

21205

RECRUITING

Johns Hopkins Hospital, Baltimore

27514

NOT_YET_RECRUITING

Lineberger Cancer, Chapel Hill

30342

RECRUITING

Northside Hospital, Atlanta

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

55455

RECRUITING

University of Minnesota, Minneapolis

73104

RECRUITING

OU Health Physicians - Infectious Disease Clinic, Oklahoma City

77030

RECRUITING

University of Texas MD Anderson MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope National Medical Center, Duarte

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02115

RECRUITING

Brigham and Women's Hospital, Boston

07601

RECRUITING

John Theurer Cancer Center, Hackensack

All Listed Sponsors
collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

Pulmotect, Inc.

INDUSTRY